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In vivo neutralization of the 
protagonist role of macrophages 
during the chronic inflammatory 
stage of Huntington’s disease
Jeffrey Pido-Lopez, Ralph Andre, Agnesska C. Benjamin  , Nadira Ali, Sahar Farag, 
Sarah J. Tabrizi  & Gillian P. Bates  
Neurodegenerative diseases, characterised by the progressive and selective neuronal death in the 
central nervous system, are frequently accompanied by an activated immune system. In Huntington’s 
disease (HD), clinical and animal studies show evidence of immune activity, along with hyper-reactive 
monocyte/macrophage responses, while application of immunosuppressive regimens have imparted 
beneficial effects to HD mice. These findings suggest a contributory role of the immune system in HD 
pathology, with immune-based interventions offering a potential therapeutic strategy. Herein, we 
show that peripheral and CNS immune system activity increased with disease progression in HD mouse 
models and defined the phenotype of the immune response. Additionally, the depletion of monocytes 
and macrophages in vivo, via clodronate liposome treatment, revealed a major contributory role of 
these innate immune cells to the chronic inflammatory milieu observed during the course of the disease. 
This suggests that peripheral immunomodulatory strategies targeting monocytes and macrophages 
could be relevant for HD.
The contribution of the immune system to the pathology of neurodegenerative diseases such as Alzheimer’s dis-
ease, Parkinson’s disease and Huntington’s disease (HD) has gathered increasing interest and momentum with 
the ultimate hope of finding effective immune-based therapeutic strategies1–5. HD is an autosomal dominant 
neurodegenerative disorder characterized by progressive cognitive, psychiatric and motor impairments caused 
by neuronal dysfunction and cell death. The causative mutation is a CAG trinucleotide repeat expansion in exon 1 
of the huntingtin (HTT) gene leading to an expanded stretch of 38 or more glutamine residues in the N-terminal 
region of the HTT protein6.
HTT is more highly expressed in neurons as compared to other cell types7. However, immune cells including B 
cells, T cells, monocytes and/or macrophages from patients show detectable levels of HTT that are positively cor-
related to disease burden and brain caudate atrophy8,9. While microglial cells, the major component of the central 
nervous system (CNS) immunity, have long been observed to be activated in presymptomatic HD10, more recent 
results suggest a role for the peripheral immune system in HD progression. This has taken the form of elevated 
levels of plasma cytokines9 and chemokines11 such as IL6 and TNFα in HD mouse models and patients, along 
with dysregulated monocyte and macrophage in vitro responses9,12,13. Indeed, studies utilising immunomodula-
toy regimens in HD mouse models substantiate this premise. Beneficial effects have been obtained through the 
replacement of the HD immune system with a normal one, via bone marrow transplantation14, or by treatment 
with immunosuppressive agents15,16 whose effects have been specifically limited to immune cells outside of the 
brain. The ability of mutant HTT to promote the activation/signalling of the pro-inflammatory transcription 
factor NFκB may provide one mechanism for the enhanced monocyte/macrophage cytokine secretions seen in 
HD13.
Knock-in HD mice precisely model the genetic basis of HD. They have been generated by either inserting a 
highly expanded CAG repeat into the mouse Htt gene, e.g. HdhQ15017, or by replacing mouse exon 1 Htt with a 
mutated version of human exon1 HTT e.g. zQ17518. Incomplete splicing of the Htt gene in all knock-in models19 
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and HD patient brains20 results in the production of a small polyadenylated transcript that encodes the highly 
pathogenic exon 1 HTT protein. The R6/2 HD mouse line is transgenic for the 5′ region of the HTT gene21, 
expresses an exon 1 HTT protein and is a model of this incomplete splicing event. R6/2 mice with approximately 
(CAG)200 and knock-in mice with similar CAG repeat expansions (e.g. HdhQ150 and zQ175) develop highly 
comparable behavioural, molecular and neuropathological phenotypes22, but over different time scales: late-stage 
disease is at ~14 weeks of age for R6/2 mice and close to two years for the HdhQ150 and zQ175 knock-in lines.
Herein, we assessed HD mouse monocyte, macrophage and other immune cells from blood, brain and/
or spleen during early symptomatic and late stage HD for signs of immune activity, as indicated by increased 
immune cell activation markers and cytokine production. We find dysregulated monocyte/macrophage activity 
in agreement with previous studies9,13, but also detect increased dendritic cell (DC) activation. The major role 
of macrophages and DCs as antigen presenting cells during T cell activation, coupled with our observation of 
increases in cytokines that are predominantly secreted by T cells, prompted us to additionally investigate T cell 
activation during HD. Our results revealed that these cells were also dysregulated and showed an increase in 
activity during the latter stages of disease. Subsequently, we used clodronate liposomes23,24 to selectively deplete 
phagocytic monocyte/macrophage and DC populations from blood and tissues, resulting in cytokine normal-
isation, and demonstrating that macrophages contribute to the in vivo chronic inflammatory milieu that we 
observed in R6/2 mice from an early symptomatic stage of disease.
Results
Dysregulation of brain and plasma cytokine levels in late stage R6/2 mice. Neuroinflammation 
due to the activation of microglial cells in the brain of HD patients10 and mice25, as well as the possible activation 
of hyper-responsive monocytes and macrophages9,12, may lead to increased production of cytokines in both the 
periphery and the CNS of HD subjects. In order to investigate this, we measured plasma and brain cytokine levels 
by mesoscale discovery (MSD) multiplex ELISA and quantitative real-time PCR (qPCR) respectively. The MSD 
results revealed a rise in blood IL6 by approximately two-fold in late symptomatic 14 week-old R6/2 mice, while 
IL1β and TNFα levels were also elevated by just under 50% and IL2 and IL10 increased by over 70% (Fig. 1a).
In the brain, IL6 and TNFα have been documented to have detrimental neurotoxic effects26–28. Quantification 
of cytokine mRNA levels in striatum, cortex and cerebellum showed increased production of Tnfα only in the 
striatum by more than twofold, but there was no increase in Il6 expression in any of the brain regions tested 
(Fig. 1b). Furthermore, an approximately threefold increase in Il12 expression was evident in the striatum of R6/2 
mice while the reverse pattern was seen in the cortex, with decreases occurring in Il12 and Il1β by approximately 
60% and 40% respectively.
In the periphery, R6/2 splenocyte Il10, Il12 and Il17 expression levels were at least 50% higher than WT, 
whereas Il1β, Il4, Il6 and Tnfα levels remained unchanged. In contrast, cell samples from the peritoneal cavity 
enriched for macrophages, had approximately four times more Il4, and almost ten-fold higher Il6 than in WT, 
with more modest increases for Il10 and Il12 of approximately 1.8 and 1.3 fold respectively (Fig. 1c). As observed 
for splenocytes, Tnfα and Il1β levels were not affected. The results may suggest that blood IL6 upregulation in late 
stage HD is primarily due to increased macrophage secretion, as increases were only observed in the macrophage 
enriched samples, and not in splenocytes, where macrophages make up only a small percentage of the cell popula-
tion. Conversely, the increase in splenocyte Il12 and Il10 levels could suggest that cells additional to macrophages, 
such as helper T cells, are contributing to the increases in the plasma levels of these cytokines.
The cytokine gene expression results for macrophages in the periphery and microglial cells in the brain 
indicate phenotypically different populations of activated macrophages/microglia in these two compartments, 
with cells at the periphery exhibiting a more M2-like phenotype, while microglia in the brain favour an M1 
phenotype29.
Increased frequencies of activated immune cells in late-stage R6/2 mice. Although the gene 
expression results for the macrophage enriched peritoneal cells identify myeloid cells as a major source of the 
upregulated blood cytokines during late stage HD, the possible contribution of other cytokine secreting immune 
cells such as T lymphocytes and dendritic cells (DC) cannot be completely dismissed. More importantly, some 
cytokines that were elevated in the periphery in R6/2 mice, such as IL2 in blood and splenic Il17 mRNA, are 
not typically secreted by macrophages. This finding prompted us to identify the other cells responsible for the 
increased peripheral cytokine levels.
Following activation, DC and macrophage/microglia upregulate their expression of several activation markers 
including OX40 ligand (L) and CD40, while, similarly, activated T cells can be identified via the increased expres-
sion of cell surface markers such as OX40, CD40L and CD2530–34. Gene expression levels for Ox40L and Cd40 
in the spleen, peritoneal macrophages and brain regions were measured in order to detect DC and macrophage/
microglia activation, and Ox40 in the spleen to detect T cell activity. In the spleen, which contains T cells and 
a small percentage of DCs and macrophages, expression of Ox40L and Cd40 were increased in R6/2 mice by 
approximately four-fold and two-fold respectively (Fig. 2a). Similarly, Cd40 and Ox40L levels were elevated in 
the peritoneal macrophage enriched cell population (Fig. 2b). Therefore, DC and/or macrophage cell activation 
can be detected in both spleen and peritoneal macrophages during late-stage HD. Surprisingly, Ox40 expression 
did not increase in the spleen (data not shown), suggesting a lack of splenic T cell activity. In the striatum, an 
increase in Cd40 expression was also evident (Fig. 2c), which could not be observed in the cortex or cerebellum 
(data not shown), consistent with the observation of increased cytokine production being confined to the stria-
tum (Fig. 1b). We failed to detect any Ox40L expression in any of the brain regions assessed in either WT or R6/2 
mice (data not shown).
In order to verify the qPCR results, FACS analysis of OX40L and CD40 expression was performed for 
(CD11b+, CD11c−, CD3−, Ly6G−) splenic and peritoneal macrophages and (CD11b+, CD11c+, CD3−, Ly6G−) 
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splenic DCs. Additionally, CD3 and CD4 or CD8 expressing splenic T cells were assessed for OX40 cell surface 
expression. Figure 2d depicts a representative FACS analysis (n = 5/group) of purified peritoneal macrophages 
from 14 week old R6/2 mice showing that 52% of the cells are active based on their high expression of CD40 as 
compared to 10% in WT mice. These results indicate a probable role for macrophages in elevating the plasma 
cytokine levels during HD. Further assessment of OX40L high expressing activated macrophages showed an 
increase in their frequency in the peritoneal cavity during late-stage HD (Figure S1).
Assessment of splenic DCs (CD11b+ CD11c+ CD8− Ly6G−) for high expression of OX40L and CD40 by FACS 
also revealed increases in the numbers of OX40L high and CD40 high cells in late-stage R6/2 mice compared to 
WT (Fig. 2e). R6/2 mice at 14 weeks of age had almost two fold more activated DCs that were OX40L high, and 
over three times more activated DCs that were CD40 high than WT.
The FACS analysis of CD3+, CD4+ helper or CD3+, CD8+ cytotoxic T cells for high expression of OX40, as a 
marker for activated T cells, revealed significantly higher percentages of OX40 high expressing CD4 and CD8 T 
cells in the 14 week old R6/2 mice versus WT. Both cell populations showed approximately twice as many acti-
vated cells in their total helper (~7% ± 1 for WT and ~14% ± 3 for R6/2) and cytotoxic (~12% ± 4 for WT and 
Figure 1. Immune activation in late-stage HD mice as indicated by cytokine levels. (a) Cytokine upregulation in 
the blood of 14 week old R6/2 mice. Plasma levels for R6/2 mice compared to WT are shown ± SEM, (n = 20/group 
IL1β; 16/group IL2; 19/group IL6; 26/group IL10 and 28/group TNFα). (b) Increases in cytokine gene expression 
was limited to the striatum of late-stage R6/2 mice. Il1β, Il2, Il4, Il6, Il10, Il12, Il17 and Tnfα gene expression 
levels in cerebellum, striatum and cortex of R6/2 mice (n = 5/group) compared to WT (n = 5/group) ± SEM as 
measured by qPCR. (c) Increased cytokine gene expression in R6/2 splenic and peritoneal macrophage enriched 
cell populations. R6/2 mouse splenic (n = 10/group) and peritoneal macrophage (n = 7/group) gene expression for 
cytokines relative to WT ± SEM quantified by qPCR. *p < 0.05 and **p < 0.01 vs WT by Student’s t test. WT = wild 
type, pM0 = peritoneal macrophages.
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Figure 2. Increased activity of immune cells in late-stage R6/2 mice. (a) Increased splenic Ox40L and Cd40 gene 
expression in late-stage R6/2 compared to WT. Splenic Ox40L (n = 8/group) and Cd40 (n = 5/group) in R6/2 mice 
relative to WT ± SEM as measured by qPCR. (b) Increased Cd40 (n = 5/group) and Ox40L gene (n = 5/group) 
expression in peritoneal macrophages enriched cell populations in late-stage R6/2 compared to WT ± SEM 
as measured by qPCR. (c) Higher Cd40 expression (n = 5/group) in striatum of 14 week old R6/2 mice vs. 
WT ± SEM as analysed by qPCR. (d) Increased frequencies of activated CD40hi peritoneal macrophages in late-
stage R6/2 mice. Percentage of peritoneal macrophages (gated as; CD11b+, CD49b−, CD8−, CD11c−, Ly6G−) 
highly expressing cell surface CD40 in 14 week old R6/2 mice and WT as assessed by FACS. The Figure shows a 
typical example of FACS dot plots obtained for each group analysed. (e) Increased frequencies of activated OX40L 
high and CD40 high splenic DC in late-stage R6/2 mice. Mean percentage ± SEM of DC (gated as; CD11b+, 
CD8−, CD11c+, Ly6G−) highly expressing cell surface OX40L and CD40 in 14 week old WT (n = 4/group) and 
R6/2 mice (n = 6/group) as assessed by FACS. (f) Increased frequencies of activated OX40 high CD4 and CD8 
splenic T cells in late-stage R6/2 mice. Mean percentage ± SEM of T cells (gated as; CD3+, CD4+ or CD8+) 
highly expressing cell surface OX40 in 14 week old WT (n = 5/group) and R6/2 mice (n = 6/group) as assessed 
by FACS. *p < 0.05 and **p < 0.01 vs WT by Student’s t test. WT = wild type, pM0 = peritoneal macrophages, 
DC = dendritic cells.
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~30% ± 5 for R6/2) T cell pools in the R6/2 mice (Fig. 2f). These FACS results are contrary to the level of Ox40 
expression, which was not increased in R6/2 spleens as compared to WT.
Peripheral immune activation precedes immune activity in the brain of R6/2 mice. We have 
previously observed that the activation of the peripheral immune system, as evidenced by significant increases 
in a plethora of cytokines in blood, occurs in both HD patients and mouse models from early stages of disease, 
with macrophages and microglial cells prone to hyperactivity following their in vitro stimulation9,12. We there-
fore sought to determine whether immune activity in the R6/2 mouse brain could also be detected at an earlier 
stage. Therefore, we assessed gene expression and/or protein cytokine levels, and immune activation markers in 
8-week-old early symptomatic R6/2 mouse brains, blood and lymphoid tissues/cells. We focused on the cytokines 
and activation markers that we had found to be upregulated in late stage R6/2 mice. Gene expression analysis 
showed little change in striatal cytokine expression in R6/2 as compared to WT (data not shown). However, 
increases in the expression of cytokines and activation markers were identified in R6/2 splenocytes and/or perito-
neal macrophages by 8 weeks of age. Il6 was increased in the peritoneal macrophage enriched cell sample by over 
two fold (Fig. 3a), splenic Il12 was increased by over 70% (Fig. 3b), Cd40 was increased in the spleen by over 90% 
(Fig. 3c) and in peritoneal macrophages by approximately 25% (Fig. 3d).
Quantification of protein levels in blood from 8-week-old R6/2 mice showed no increase in IL6, IL10, IL1β 
and TNFα cytokines levels (data not shown), despite the apparent increased gene expression for some of these 
cytokines within peripheral cell populations. This finding suggests that the immune system has not been acti-
vated for long enough to allow cytokines to accumulate. In contrast, the cell surface expression of CD40 on 
macrophages and DCs mirrors the gene expression findings: with a 20% increase in the percentage of activated 
macrophages and approximately 30% increase in the percentage of activated DCs, indicating that these cells may 
have become recently activated (Fig. 3e).
The percentages of OX40 high expressing cells were increased for the CD4 T cells (p = 0.06) but not for the 
CD8 T cell population, indicating that helper T cells are on the cusp of activation at this stage of disease (Fig. 3f). 
Interestingly, unlike for Cd40 (Fig. 3c,d), Ox40L gene expression, and cell surface protein expression on mac-
rophages and DCs remained similar to WT levels (data not shown). This further supports the notion that we 
have analyzed these cell populations at the early stages of immune activity, since OX40L upregulation on antigen 
presenting cells (APC) usually occurs at a later stage of activation, after CD40 surface expression increases33,34. 
Furthermore, FACS assessment of peritoneal macrophages from 8-week-old mice also revealed similar results 
with increases in the percentages of CD40 highly expressing cells in the R6/2 mice versus WT controls (Fig. 3e) 
but with no differences in OX40L highly expressing peritoneal macrophage frequencies in the R6/2 and WT 
groups (Figure S2).
Assessment of exon 1 mutant HTT gene expression within R6/2 peritoneal macrophages and splenic mono-
nuclear cells, containing lymphocytes, macrophages and DC, confirmed that the R6/2 transgene was expressed in 
these cells and as expected was absent from their WT counterparts (Fig. 3g).
Late stage zQ175 mice recapitulate the immune activation characteristics observed in 
14-week-old R6/2 mice. In order to confirm the relevance of phenotypes identified in R6/2 mice, we ascer-
tained whether these also develop in a knock-in HD mouse model, which more closely recapitulates the genetic 
basis of HD. The expression levels of cytokines in splenocytes from late-stage zQ175 mice at 22 months of age 
showed similar increases to those observed in late-stage R6/2 mice: Il10 by over 50%, Il12 by almost three-fold, 
and Il17 by approximately 50%. In contrast to R6/2 mice, Tnfα was also increased (Fig. 4a). In the peritoneal mac-
rophage enriched cell populations, Il6 gene expression was almost three-fold higher, Il10 over six-fold higher and 
Il12 around five-fold higher in the zQ175 mice versus WT (Fig. 4a). These results indicate that the M1 activated 
macrophage phenotype is more evident in zQ175 than in R6/2 mice, as indicated by a greater increase in Il12, 
as well as the upregulation of Tnfα expression in spleen. This suggests that the zQ175 mice have a less stringent 
M1 or M2 macrophage response. The frequencies of activated T cells, macrophages and DCs in the spleen or 
peritoneal cavity were also upregulated in late-stage zQ175 mice as compared to WT, according to the cell sur-
face expression of activation markers: OX40 (Fig. 4b) and OX40L (Fig. 4c) respectively, which were increased. 
Analysis of cytokine gene expression in brain regions of zQ175 mice at 12 months of age revealed that only Tnfα 
expression was increased in the striatum, as had been the case for R6/2 mice. However, unlike R6/2 mice, Il12 was 
not upregulated in the striatum, and nor was it decreased in the cortex of zQ175 mice (Fig. 4d). We were unable 
to observe any increase in striatal cytokine levels in late stage 21 month old zQ175 mice (Fig. 4e), which may 
be due to the effect of immune exhaustion in these old zQ175 mice as a result of chronic immune activation of 
self-renewing HD microglial cells35.
In vivo depletion of macrophages and DC via clodronate liposome infusion normalizes cytokine 
levels during late stage HD. Our current and previous results13 strongly implicate macrophages as the 
major contributors to the immune dysregulation that occurs in HD. In order to ascertain the role of these cells, 
we utilized the toxic clodronate immunosuppressive drug, commonly used for the treatment of osteoporosis36. 
In order to specifically deplete monocyte and macrophage cells in vivo, clodronate packaged in liposomes were 
administered via IV or IP injection into R6/2 mice at 13–14 weeks of age37–39. IV injection resulted in the deple-
tion of (CD11b+ CD8− CD11c− Ly6G−) blood monocytes and splenic macrophages, and (CD11b+ CD8− CD11c+ 
Ly6G−) splenic DCs, in both the blood and spleen of R6/2 mice (Fig. 5a) and WT (data not shown), but not T cells 
or neutrophils (data not shown). PBS liposome treatment had no impact on the frequencies of blood monocytes, 
and splenic macrophages and DCs (Fig. 5a). Depletion of splenic DCs and splenic macrophages was achieved 
one and two days post clodronate injection respectively, with maximal depletion of around 75% for macrophages 
and almost 90% of DCs occurring on the third day, this being maintained until day four post injection. Blood 
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monocyte depletion was observed earlier, one day after clodronate injection. The recovery of blood monocytes 
two days post injection may indicate a response by the bone marrow to replete monocyte numbers, while its 
subsequent gradual reduction from day two may be due to the recruitment of monocytes into tissues, in order to 
replenish the diminished macrophage numbers post clodronate liposome depletion24,39.
Figure 3. Immune activity in the periphery of early stage R6/2 mice. Upregulated cytokine and activated 
macrophage cell marker gene expression levels in 8-week-old R6/2 mice. Gene expression of (a) Il6 in peritoneal 
macrophages (n = 10/group), (b) Il12 (n = 5/group) and (c) Cd40 in splenic cells (n = 5/group), (d) Cd40 in 
peritoneal macrophages (n = 10/group) in R6/2 mice compared to WT. (e) Increased frequencies of activated 
macrophages and DC in early-symptomatic stage R6/2 mice. Mean % ± SEM of peritoneal macrophages (gated as; 
CD11b+, CD8−, CD11c−, Ly6G−) and splenic DC (gated as; CD11b+, CD8−, CD11c+, Ly6G−) highly expressing 
cell surface CD40 in 8 week old WT (n = 5/group) and R6/2 mice (n = 6/group) as assessed by FACS. (f) Increased 
frequencies of activated T cells in early-symptomatic stage R6/2 mice. Mean percentage ± SEM of splenic T cells 
(gated as; CD3+, CD4+ or CD3+, CD8+) highly expressing cell surface OX40 in 8 week old WT (n = 5/group) 
and R6/2 mice (n = 8/group) as assessed by FACS. (g) Presence of exon 1 mutant huntingtin (mHTT) in splenic 
mononuclear cells and peritoneal macrophages in 8 week old R6/2 (n = 6) but not in WT (n = 5) mice as assessed 
by qPCR, mean CT values ± SEM are shown for both mHTT and the geometric mean of ATP5B and B2M 
housekeeping genes (HK). Agarose gel electrophoresis of the corresponding mHTT qPCR products are shown 
below each graph. #p = 0.06, *p < 0.05 vs WT by Student’s t test. WT = wild type, pM0 = peritoneal macrophages.
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Figure 4. Immune activation in zQ175 mice. (a) Increased gene expression in late-stage zQ175 mice for several 
cytokines in splenic (n = 5–6/group) and peritoneal (n = 5–6/group) macrophage populations. 22-month-
old zQ175 mice ± SEM splenic and peritoneal macrophage gene expression for cytokines relative to WT as 
quantified by qPCR. (b) Increased activated T cell numbers in 22-month-old Q175 mice. Mean % ± SEM of 
splenic T cells (gated as; CD3+, CD4+ or CD8+) expressing OX40 highly in 22 month old WT (n = 5/group) 
and zQ175 mice (n = 6/group) as assessed by FACS. (c) Increased activated peritoneal macrophage and DC 
frequencies in 22-month-old zQ175 mice. Mean percentage ± SEM of peritoneal macrophage and splenic 
DC expressing OX40L highly in 22 month old WT (n = 5/group) and zQ175 mice (n = 5/group) as assessed 
by FACS. (d) Increases in cytokine gene expression was limited to the striatum of 12 month old zQ175 mice. 
Mean Il1β, Il6, Il10, Il12 and Tnfα gene expression levels in cerebellum, striatum and cortex of zQ175 mice 
(n = 5/group) compared to WT (n = 5/group) ± SEM as measured by qPCR. (e) There were no increases in 
cytokine gene expression in 21 month old zQ175 mice. Mean Il1β, Il6, Il10, Il12 and Tnfα gene expression 
levels in cerebellum, striatum and cortex of zQ175 mice (n = 5/group) compared to WT (n = 5/group) ± SEM 
as measured by qPCR. *p < 0.05 and **p < 0.01 vs WT by Student’s t test. WT = wild type, pM0 = peritoneal 
macrophages, DC = dendritic cells.
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Analysis of plasma cytokine levels following clodronate liposome treatment revealed that the drug initially 
promoted a gradual increase in all of the cytokines assessed (Fig. 5b). This peaked two days post injection, rising 
from approximately 20 pg/mL to over 80 pg/mL for IL10, from 2 pg/mL to 13 pg/mL for IL1β, by over 60% for 
IL2, by approximately 130 pg/mL for TNFα and by over fifty-fold for IL6 (Fig. 5b). No significant changes were 
evident in the PBS liposome treated control mice at day 2 and day 4 post injection (Fig. 5b). This observation can 
be explained by the activation of the immune system by dead or dying monocytes and macrophages, increasing 
Figure 5. Clodronate liposome depletion of splenic macrophage and DC results in reduced IL6 levels in R6/2 
mice. (a) IV clodronate liposome treatment of late-stage R6/2 mice depletes splenic macrophages (gated as; 
CD11b+, CD8−, CD11c−, Ly6G−) and DC (gated as; CD11b+, CD8−, CD11c+, Ly6G−), and monocytes (gated 
as; CD11b+, CD8−, CD11c−, Ly6G−). Mean percentage ± SEM of splenic macrophages and DC, and monocytes 
in the total leukocyte population following clodronate liposome or PBS liposome injection into late-stage R6/2 
mice as analyzed by FACS. (b) Clodronate liposome treatment only normalises IL6 to WT plasma levels in late-
stage R6/2 mice. Mean concentration of TNFα, IL1β, IL2, IL6 and IL10 ± SEM following clodronate liposome 
or PBS liposome injection as assessed by MSD. *p < 0.05 decrease, #p < 0.05 increase as compared to R6/2 day 0, 
(n = 5/group). WT = wild type, IV = intravenous, DC = dendritic cells, M0 = macrophages. MNC = monocytes, 
Clod/lip = clodronate liposome, PBS/lip = PBS liposome.
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cytokine production by immune cells, which includes any remaining monocytes and macrophages40. Such initial, 
dramatic cytokine spikes could potentially have detrimental effects, however no adverse effects were observed up 
to ten days post drug injection. At day 3 post injection, when maximum splenic macrophage and DC depletion 
was observed, most of the cytokines returned to basal levels, while at day 4 post injection IL6 levels had signif-
icantly decreased from that observed prior to injection. It is worth noting, that of the cytokines assessed here, 
only Il6, and Il10 levels were elevated in the peritoneal macrophage enriched cell population of late stage R6/2 
mice compared to WT (Fig. 1c). Therefore, the greater likelihood of a reduction in IL6 and IL10, but not TNFα, 
IL1β or IL2 post macrophage depletion, was perhaps to be expected. However, the lack of a reduction in IL10 
levels suggests that other cells, such as T cells and B cells, may upregulate this cytokine in order to compensate 
for the loss of macrophage IL10 production following the depletion of these cells41,42. Our inability to detect any 
differences in plasma basal levels in R6/2 compared to WT mice for the other upregulated cytokines (Fig. 1a) is 
likely due to the low sample size for this experiment. The detection of differences for only plasma IL6 and IL10 
(Fig. 5b), the cytokines that show the greatest disparity between R6/2 and WT at 14 weeks of age would support 
this conclusion.
In order to resolve the limitation of a small sample size, we repeated the clodronate liposome infusion study 
twice and pooled the experimental results. However, the splenic macrophage and DC depletion dynamics 
were somewhat variable between experiments. Maximal splenic macrophage (decreasing to 0.8–0.9% CD11b+ 
CD8− CD11c− Ly6G− cells from 3.9–4.5% prior injection) and DC depletion (decreasing to 0.1–0.2% CD11b+ 
CD8− CD11c+ Ly6G− cells from 0.6–0.8% prior injection) was achieved in all experiments, but occurred at dif-
ferent time-points, between one to three days post injection (data not shown). This difference may be due to 
batch-to-batch drug variations. Despite the difference in depletion timing, macrophage frequencies and cytokine 
levels did not differ significantly at the start of the experiment, or at the time when highest cell depletion was seen 
between individual experiments.
Therefore, we decided to look specifically at the cytokine levels prior to treatment, for all three experiments, 
on the day when maximal macrophage depletion was achieved and on the day following maximal macrophage 
depletion. Our combined results not only confirmed the significant reductions in IL6 levels at the day following 
maximal macrophage depletion, but additionally, revealed decreases in IL1β and IL2, not only at this time-point, 
but also on the day of maximal splenic macrophage depletion (Fig. 6a). The reduction of IL1β and IL2 one day 
ahead of IL6, may be explained by their shorter half-life when compared with IL643–45, thus resulting in their more 
rapid loss post significant macrophage depletion.
Next, we assessed whether clodronate injection via the IP route produced similar results to those of IV injected 
mice. An IP injection will result in macrophages and DCs within tissues being depleted without affecting blood 
monocytes, and will reveal whether this is sufficient to account for the effect of clodronate liposomes on R6/2 
cytokine levels46. The dynamics of cell depletion in the spleen post IP injection were variable, similar to those 
seen by IV. The maximal depletion of macrophages (from 4% ± 0.3% to 1.1% ± 0.4%) and DCs (0.4% ± 0.09% 
to 0.2 ± 0.04%) were at comparable levels to those for IV, but occurred later, on days three and four post injec-
tion, as expected, there was no effect on blood monocyte numbers (data not shown). Plasma cytokine levels 
were measured by MSD multiplex analysis on the day when maximal cell depletion was achieved, as well as the 
following day. IL6 levels were decreased one day after maximum splenic macrophage depletion, but there was 
no effect on IL1β as had been observed for the IV injected mice. This may be due to IL1β being predominantly 
secreted by blood monocytes, which remain intact post IP clodronate treatment or, to the greater macrophage 
depletion within spleens via the IV route compared to the IP route (data not shown). However, TNFα levels were 
also reduced following cell depletion, which had not occurred after IV injection (Fig. 6b). Taking the IP and IV 
results together, these findings suggest that reductions in specific cytokines post clodronate treatment only occur 
if these cytokines are at higher levels in R6/2 plasma as compared to WT at treatment initiation. The results indi-
cate that depletion of macrophages and DCs within the spleen, and probably other tissues, is sufficient to prevent 
the increased plasma cytokine levels in R6/2 mice, suggesting that macrophages and/or DCs are central to the 
observed increases in IL1β, IL2, IL6, and TNFα levels.
Discussion
Herein we have shown that the cells that promote immune hyperactivation during disease progression in HD 
mouse models are not only macrophages and monocytes, as inferred by previous studies, but also T cells and DCs. 
We additionally characterised the macrophage response in HD according to the M1 and M2 phenotypic classifi-
cation, and found that this differed depending on the tissue in which these cells reside. In R6/2 mice, within the 
brain, microglial cells took up a predominantly M1 cytotoxic profile, whilst in the periphery, macrophages favour 
an M2 humoral/repair phenotype29. Thus, while microglial cells produced elevated Il12 and Tnfα but lacked 
Il10 and Il6 increases, their peripheral counterparts increased their production of Il6 and Il10 as well as the M2 
promoting cytokine Il4, but lacked Tnfα upregulation. This indicated a phenotypic discordance in the activated 
macrophage cells populating these two distinct regions. Although the M1/M2 paradigm has been traditionally 
used to identify seemingly two phenotypically distinct macrophage populations generated following their activa-
tion, such differences have been shown to be less clear cut more recently47,48. In keeping with this, in the zQ175 
mice the M1/M2 paradigm was less evident, but nevertheless some remnants of a peripheral M2 peritoneal mac-
rophage and an M1 like microglial response could still be seen.
The absence of Il10 upregulation within the brain despite, its increases in the periphery, not only support the 
idea that microglial cells are predominantly M1 in phenotype but may also indicate that these cells are not trying 
to counter the inflammation within the CNS, at least via the secretion of anti-inflammatory IL10. Interestingly, 
the study by Bjorkvist et al. in three different HD mouse models, not only saw similar increases in the levels 
of blood M2 type cytokines, IL6 and IL10 in the periphery but also found no significant increases in the M1 
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promoting cytokine IFNγ and, unlike in our study, TNFα as well, thus further supporting the notion that acti-
vated peripheral monocytes/macrophages show an M2 dominant phenotype9.
Inflammation and immune activation has been reported to be a feature of HD and our analysis of cytokine 
levels in the brain and plasma of late-stage R6/2 and zQ175 mice further confirmed this finding. Of particular 
interest, this included increases in IL6 and TNFα, which are known to have neurotoxic properties26,28 and have 
the capacity to cross the blood brain barrier49,50. Interestingly, TNFα expression was increased in the brain and 
elevated levels of this cytokine were found in the blood, despite no increase in Tnfα gene expression in the periph-
eral immune compartments assessed. Therefore, TNFα may have migrated from the brain to the blood. However, 
other peripheral TNFα sources such as lymph nodes cannot be discounted as the possible source for the raised 
blood TNFα levels.
IL17 has been found to be secreted by astrocytes within the brain51, however we failed to detect Il17 gene 
expression in either WT or R6/2 mice in our qPCR analysis which might suggest a minimal role of these glial 
cell population to the observed cytokine upregulation in the HD brain, since they are also coincidently capable 
of secreting cytokines such as TNFα52. Clearly, determining the mechanisms for the observed site-specific differ-
ences in HD brain cytokine production requires further elucidation.
Subsequent analyses to quantify the frequencies of activated immune cells, responsible for the upregulated 
cytokines, revealed not only increases in the levels of active macrophages, as predicted, but also DCs and T cells. 
These results indicate a possible contribution of these cells to the macrophage-induced inflammation seen during 
HD. Previously, we failed to detect any increases in activated macrophage frequencies based on their MHCII cell 
surface expression13. This result is particularly interesting given that unlike M1 macrophages, M2 macrophages 
do not notably upregulate MHCII on their surface post-activation. This not only provides an explanation for 
the previous results but also strengthens our current findings, suggesting that peripheral macrophages predom-
inantly adopt an M2 phenotype in R6/2 mice29,53. Late-stage zQ175 mice revealed similar increases in cytokine 
production, and activated immune cells, to their 14-week-old R6/2 counterparts. However, these mice were found 
to have a more balanced M1 and M2 macrophage response, which may be due to age differences or minor dif-
ferences in disease presentation between the two models. We previously reported that the NFκB transcription 
factor is dysregulated in HD patient monocytes/macrophages13. It would be interesting to assess whether any of 
Figure 6. Clodronate liposome normalisation of cytokine levels in late-stage R6/2 mice. (a) Clodronate liposome 
treatment reduced IL1β, IL2 and IL6 levels in late-stage R6/2 mice post IV treatment (n = 8–12/group). Mean 
concentration of IL10, IL1β, IL2, IL6 and TNFα ± SEM following clodronate liposome IV injection, at the day of 
greatest splenic M0 depletion and one day later as assessed by MSD. (b) Clodronate liposome treatment normalised 
TNFα, IL2 and IL6 levels in late-stage R6/2 mice post IP treatment (n = 9–12/group). Mean concentration of 
TNFα, IL1β, IL2, IL6 and IL10 ± SEM following clodronate liposome IP injection, at day of highest splenic M0 
depletion and one day later as assessed by MSD. All comparisons to R6/2 levels at day 0, ANOVA with Bonferroni 
correction. *p < 0.05, #p = 0.06. WT = wild type, IV = intravenous, IP = intraperitoneal, M0 = splenic macrophages.
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the other HD murine cell populations we have found to have enhanced activation levels also utilise NFκB for 
their activity.
The analysis of immune activity during specific stages of disease progression in R6/2 mice provided an insight 
into the initiation of immune activation. Initial signs of immune activity in macrophage and DC populations 
occurred at an early symptomatic stage, at which there was no immune activity in the striatum, a brain region 
that shows immune dysregulation during late-stage disease. Our finding that immune activation in the periph-
ery precedes that in the brain could suggest that the peripheral immune system may, at least in part, initiate or 
enhance the activation of brain microglia, as previously proposed by our group and others9,11, possibly through 
the secretion and provision of IL6 and other blood brain barrier penetrating cytokines. These cytokines may 
stimulate microglia directly, or indirectly, to become activated e.g. through neuronal cell killing, as could be the 
case for IL654.
Clodronate liposome depletion of macrophages and DCs in vivo, resulted in the normalisation of cytokine 
levels in late-stage R6/2 mice, and provided the first in vivo evidence to confirm that these APCs upregulate their 
cytokine levels. Our results provide a valuable insight into the impact of the dysregulated macrophage and DC 
responses on the HD immune system, identifying these cells as major accomplices in promoting the chronic 
in vivo inflammation that manifests as excessive blood cytokine content in HD mice. Follow up studies would 
be required to decipher the effect of peripheral cytokine normalisation on HD associated neuroinflammation 
and ultimately, HD disease pathology. From our experience as well as from previous immunomodulatory HD 
studies, this would require consistent, long term and continuous blood cytokine reduction. Thus multiple, sched-
uled clodronate treatments would be required to prevent the observed recovery of monocytes/macrophages 
and DC numbers in order to investigate the impact of prolonged, sustained drug induced macrophage and DC 
depletion on disease- related phenotypes. Several immunomodulatory regimens, which have achieved long-term 
immunosuppression in HD mice, have however conferred beneficial effects in improving symptoms and/or sur-
vival. We propose that such effects are, at least in part, due to their impact on macrophages and/or DCs, be it 
upstream, as in the case of bone marrow transplantation, where HD myeloid cells are replaced by wild type 
cells14, or downstream, where specific macrophage-upregulated cytokines are inhibited, such as peripheral IL6 
neutralization and TNFα signalling inhibition15,16. Although we show that clodronate liposome therapy signif-
icantly dampens mutant huntingtin induced macrophage hyperactivity, and elevated cytokine production, the 
long-term use of such a potent drug may be deleterious, considering the important role of macrophages in other 
biological functions such as red blood cell recycling55. Thus, more defined therapeutic strategies targeting the 
production of specific cytokines, or biasing their M1/M2 activation phenotype, are likely to have more desirable 
outcomes. Nevertheless, herein, we have shown that macrophages and DCs play a protagonist role in the immune 
hyper-activation and chronic inflammation associated with HD in vivo, providing a case for immunomodulatory 
regimens targeting these particular cells as potential therapeutic strategies for this disease.
Methods
Mice. Hemizygous R6/2 mice were generated by backcrossing R6/2 males to (CBA x C57BL/6) F1 females 
(B6CBAF1/OlaHsd, Harlan Olac, Bicester, UK)21. Heterozygous zQ175 knock-in mice18 were supplied from 
CHDI colonies (Jackson Laboratory, Bar Harbor, ME, USA) and maintained by backcrossing to C57BL/6J 
(Charles River). All animals had unlimited access to food and water, and were kept in sterile housing conditions 
in individually ventilated cages with environmental enrichment as previously described56. Mice were subject to a 
12-h light/dark cycle. All experimental procedures were performed in accordance with Home Office regulations 
and approved by the King’s College London and University College London Ethical Review Committees.
R6/2 and zQ175 mice were genotyped and the CAG repeat was measured as previously described57. The mean 
repeat size (±SD) for all mice used in the study was 180 ± 10 for zQ175 mice and 205 ± 7 for R6/2 mice. Mice 
were euthanized via CO2 asphyxiation or cervical dislocation as required. Equal numbers of male and female R6/2 
and zQ175 mice, and their WT littermate controls were used unless stated otherwise.
Blood, plasma, tissue and cell sample collection. Blood was obtained via tail vein puncture followed 
by decapitation post cervical dislocation and collected into EDTA tubes. Plasma was obtained by spinning blood 
at 2000 × g for 5 min obtaining the top plasma layer, while the bottom layer, containing blood cells, was used for 
subsequent FACS analysis. Following euthanasia, whole brains, striatum, cortex, cerebellum and whole spleens 
tissues were dissected. Brain samples were snap frozen in liquid nitrogen immediately after dissection and stored 
at −80 °C until required. Single cell suspensions from spleen samples were obtained as described previously58, in 
some cases mononucleated cells from isolated splenocytes were purified by density gradient centrifugation using 
Histopaque (Sigma). Peritoneal macrophages (pM0) were isolated as described previously12. All cell samples were 
treated with red blood cell lysis solution (R&D systems) in order to remove red blood cells prior to subsequent 
processing.
Plasma analyses. Cytokine (IL1β, IL2, IL6, IL10, IL12 and TNFα) levels in plasma were quantified using 
Meso Scale Discovery (MSD) assays as per the manufacturer’s protocol and analysed on a SECTOR 2400 instru-
ment (MSD).
RNA extraction and quantitative real time gene expression analysis. Total RNA from cell sample 
was extracted with the mini-RNA kit according to the manufacturer’s instruction (Qiagen). Reverse transcrip-
tion (RT) was performed using the MMLV Superscript reverse transcriptase (Invitrogen) and random hexamers 
(Operon) as described previously59. All Taqman quantitative real-time PCR (qPCR) reactions were performed 
using the Chromo4 real-time PCR detector (Biorad) and quantified via the 2−ΔΔCT method60. Gene expres-
sion for the gene of interest was normalised to the geometric mean of endogenous housekeeping genes (beta 2 
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microglobulin and Atp5b for peripheral tissue/cells or Ubc and Atp5b for brain tissue) for each sample. Primer 
and probe sets for genes of interest (Il1β, Il2, Il4, Il6, Il10, Il12, Il17, Tnfα, Cd40, Ox40 and Ox40L) and house-
keeping genes were purchased from Biorad. For mutant huntingtin gene expression analysis: forward primer 
sequence = 5′gctgcacctaccgtgagt3′, reverse primer sequence = 5′cgcaggctgcagggttac3′, and FAM labelled probe 
sequence = 5′agctccctgtccgggcgg3′ were used.
Flow cytometry (FACS). For detecting macrophage/monocytes, DCs, neutrophils61 and CD8 T 
cells62, 0.5 × 106 cells were stained with anti-mouse CD8-FITC, anti-mouse CD49b-FITC, anti-mouse 
CD11b-phycoerythrim (PE), anti-mouse CD11c-APC-Cy7 (for DC exclusion) or CD11c-Per-CP (for activated 
DC population analysis) and anti-mouse Ly6G-APC-Cy7. To detect activated macrophage and DC populations, 
anti-mouse CD40-APC or OX40L-APC antibodies were also added (all from eBioscence). To detect activated 
T cells, anti-mouse CD3-PE, anti-mouse CD4-PerCP, anti-mouse CD8-FITC and anti-mouse OX40-APC or 
anti-mouse CD25-APC antibody (all from eBioscience) staining was performed for 30 min at 4 °C after blocking 
with 10% FCS in PBS with 10 mM EDTA, then fixed with 2% paraformaldehyde in PBS with 10 mM EDTA. Cells 
were analysed using FACS Canto (Becton Dickinson) acquiring 20,000 leukocytes (gated according to forward 
and side scatters with doublets excluded according to FCS-A/FCS-H dot plots). FACS results were subsequently 
analysed with FACS Diva (Becton Dickinson). Corresponding unstained cell samples for each antibody were 
acquired to establish gating areas for positively staining cells.
In vivo clodronate liposome treatment. 13 to 14 week old female mice were injected intravenously (IV) 
via the tail vein or intraperitoneally (IP) with 200 µl or 400 µl clodronate liposome (Liposoma) at 5 mg/mL respec-
tively or with control liposomes containing PBS. Preliminary dosing studies were performed to determine the 
optimal dose required to deplete target cells over ten days. Body temperature was monitored post injection, and 
no adverse effects were seen. Mice were sacrificed by cervical dislocation at days 1, 2, 3 and 4 post treatment for IV 
injected mice or 3, 4, 5 and 6 post treatment for IP injected mice as well as day 0 (prior injection). Blood, spleen 
and liver samples were obtained as described above for plasma cytokine and/or cell (monocyte/macrophage, DC, 
CD8 T cells or neutrophil) content quantification by MSD or FACS respectively as detailed above.
Statistical Analysis. Differences between specified groups were detected using one-way ANOVA with 
Bonferroni correction (SPSS software) or Student’s t-test (Microsoft Excel software) as stated in the Figure leg-
ends. P-values of 0.05 or less were considered significant.
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